Carpéné, C.; Les, F.; Mercader, J.; Gomez-Zorita, S.; Grolleau, J.-L.; Boulet, N.; Fontaine, J.; Iglesias-Osma, M.C.; Garcia-Barrado, M.J.
Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. Pharmaceuticals 2020, 13, 41.
https://doi.org/10.3390/ph13030041
AMA Style
Carpéné C, Les F, Mercader J, Gomez-Zorita S, Grolleau J-L, Boulet N, Fontaine J, Iglesias-Osma MC, Garcia-Barrado MJ.
Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. Pharmaceuticals. 2020; 13(3):41.
https://doi.org/10.3390/ph13030041
Chicago/Turabian Style
Carpéné, Christian, Francisco Les, Josep Mercader, Saioa Gomez-Zorita, Jean-Louis Grolleau, Nathalie Boulet, Jessica Fontaine, Mari Carmen Iglesias-Osma, and Maria José Garcia-Barrado.
2020. "Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control" Pharmaceuticals 13, no. 3: 41.
https://doi.org/10.3390/ph13030041
APA Style
Carpéné, C., Les, F., Mercader, J., Gomez-Zorita, S., Grolleau, J.-L., Boulet, N., Fontaine, J., Iglesias-Osma, M. C., & Garcia-Barrado, M. J.
(2020). Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. Pharmaceuticals, 13(3), 41.
https://doi.org/10.3390/ph13030041
